SR
VKTX icon

Syntax Research’s Viking Therapeutics VKTX Stock Holding History

Syntax Research’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200
Closed -$5.3K – 182
2025
Q2 		$5.3K Hold
200
– – ﹤0.01% 156
2025
Q1 		$4.83K Hold
200
– – ﹤0.01% 162
2024
Q4 		$8.05K Buy
+200
New +$11.4K 0.01% 151

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Syntax Research's VKTX Position: Q3 2025 in Review

Syntax Research sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 200 shares — an estimated $5.3K sold.

Syntax Research first reported a position in VKTX in Q4 2024 and held it in 3 quarters. The position peaked at $8.05K in Q4 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Syntax Research reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Syntax Research sold 200 Viking Therapeutics shares in Q3 2025, an estimated $5.3K.
  • Syntax Research first reported a position in Viking Therapeutics in Q4 2024 and held it in 3 quarters.
  • Syntax Research's Viking Therapeutics position peaked at $8.05K in Q4 2024.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Syntax Research's 13F filing for Q3 2025, filed 4 Nov 2025.